Anti-amyloid immunotherapies: low benefit/risk ratio Hole Ousia 3 years ago Share this: Share on Facebook (Opens in new window) Facebook Share on X (Opens in new window) X ‘Therapy related brain damage’DateJuly 21, 2023In relation toAlzheimer's diseaseAnti-amyloid drugs: Key questionsDateDecember 6, 2023In relation toAlzheimer's diseaseAccelerated approval of anti-amyloid drugsDateDecember 6, 2023In relation toAlzheimer's disease
